1. In Vivo

China: Value-Based Procurement Reshapes Strategies Of Multinational Medtech Firms

 
• By Mainbayar Badarch

China’s growing market for medtech, estimated at $70bn in 2021, could more than double this decade if the government’s Healthy China 2030 plan stays on track.  

Map of China in magnifying glass (shutterstock)
• Source: Shutterstock

Regarding the key players, with a valuation more than triple that of the following competitor, Mindray Medical is the clear market leader in the medical device market with market value of CNY326bn ($44.8bn) in 2020. Next performers are Wantai Biological (CNY86bn), Lepu Medical (CNY79bn), BGI Group (CNY75bn), New Industries (CNY75bn), Autobio Diagnostics (CNY69bn) and Jafron Biomedical (CNY59bn).

In some areas, domestic companies are markedly improving their performance across operations. China’s 134 listed medtech companies generated $44bn in...

More from Global Vision

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.